Codiak BioSciences

Codiak BioSciences

Codiak Biosciences is a biotechnology company developing exosome therapeutics.

Codiak Biosciences is a biotechnology company developing exosome therapeutics that is headquartered in Cambridge, Massachusetts and was founded by Eric lander and Raghu Kalluri in 2015.

Funding

Series A

On November 17, 2015 Codiak BioSciences completed their series A funding round with $31 million in capital from Flagship Pioneering, ARCH Venture Partners, and Fidelity Management and Research Company.

Series B

On January 26, 2016 Codiak BioSciences completed their series B funding round with $61 million in capital from Flagship Pioneering (lead investor), ARCH Venture Partners (lead investor), Alexandria Venture, and Alaska Permanent Fund.

Series C

On November 27, 2017 Codiak BioSciences completed their series C funding round with $76.5 million in capital from Sirona Capital, Qatar Investment Authority, Flagship Pioneering, Fidelity Management and Research Company.

Timeline

November 27, 2017

Series C funding round

On November 27, 2017 Codiak BioSciences completed their series C funding round with $76.5 million in capital from Sirona Capital, Qatar Investment Authority, Flagship Pioneering, Fidelity Management and Research Company.

January 26, 2016

Series B funding round

On January 26, 2016 Codiak BioSciences completed their series B funding round with $61 million in capital from Flagship Pioneering (lead investor), ARCH Venture Partners (lead investor), Alexandria Venture, and Alaska Permanent Fund.

November 17, 2015

Series A funding round

On November 17, 2015 Codiak BioSciences completed their series A funding round with $31 million in capital from Flagship Pioneering, ARCH Venture Partners, and Fidelity Management and Research Company.

2015

Codiak BioSciences was founded.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Codiak BioSciences Presents First Data on exoSTING - A Novel Engineered Exosome Therapeutic Targeting Checkpoint Refractory Tumors at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

Codiak BioSciences, Inc.

Web

What You Need to Know About Codiak BioSciences

Mark Terry

Web

Xconomy: VCs Put More Dollars Into Exosomes as Codiak Bio Lands $76M

Ben Fidler

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
June 23, 2020
FierceBiotech
Sarepta is on the hunt for new ways to deliver genetic medicines. Its latest target? A system the body's cells use to communicate with each other. The company is teaming up with Codiak Biosciences to develop engineered exosomes that can deliver gene therapy, gene editing or RNA-based treatments.
BioSpace Editorial Staff
June 1, 2020
BioSpace
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.